14159 lp - see footnotes investment history in Acadia pharmaceuticals inc

Filed on 2016-01-08 by 14159, L.P. SEC CIK 1551138 Form 4

Accession 0001638599-16-000500.txt Sec File: edgar/data/1551138/0001638599-16-000500-index.htm

2016-01-07 14159 Lp (CIK 1551138) through See Footnotes

Invested in Acadia Pharmaceuticals Inc bought 1801161 shares at $29.00 remaining shares owned 20278008

Common Stock Acadia Pharmaceuticals Inc Acad Transaction code: P Open market or private purchase of securities

f2 on january 7, 2016, 667, l.p. ("667") and baker brothers life sciences, l.p. ("life sciences", and together with 667, the "funds") purchased 785,045 and 1,801,161 shares of the common stock, respectively of acadia pharmaceuticals, inc. (the "issuer"), pursuant to an underwritten public offering.
f4 after giving effect to the transactions reported herein and as a result of their ownership interest in baker brothers life sciences capital (gp), llc, julian c. baker and felix j. baker each may be deemed to have an indirect pecuniary interest in the issuer's shares of common stock reported in column 5 of table i directly held by life sciences, a limited partnership of which the sole general partner is baker brothers life sciences capital, l.p., a limited partnership of which the sole general partner is baker brothers life sciences capital (gp), llc, due to baker brothers life sciences capital, l.p.'s right to receive an allocation of a portion of the profits from lifesciences.
f5 baker bros. advisors lp (the "adviser") serves as the investment adviser to the funds. in connection with the services provided by the adviser, the adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the funds. baker bros. advisors (gp) llc (the "adviser gp") is the adviser's sole general partner. julian c. baker and felix j. baker are principals of the adviser gp. the adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the funds. the general partners of the funds have relinquished to the adviser all discretion and authority with respect to the investment and voting power of the securities held by the funds. pursuant to agreements between julian c. baker, dr. biggar and the adviser, the adviser has investment and dispositive power over the stock options and any shares received as a result of the exercise of options. (continued in footnote 6)
f6 julian c. baker, felix j. baker, the adviser gp and the adviser disclaim beneficial ownership of the securities held directly by the funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of julian c. baker, felix j. baker, the adviser gp or the adviser is a beneficial owner of such securities for purposes of section 16 or any other purpose.


Filed on 2016-01-08 by 14159, L.P. SEC CIK 1551138 Form 4

Accession 0001638599-16-000500.txt Sec File: edgar/data/1551138/0001638599-16-000500-index.htm

2016-01-07 14159 Lp (CIK 1551138) through See Footnotes

Invested in Acadia Pharmaceuticals Inc bought 785045 shares at $29.00 remaining shares owned 2337100

Common Stock Acadia Pharmaceuticals Inc Acad Transaction code: P Open market or private purchase of securities

f2 on january 7, 2016, 667, l.p. ("667") and baker brothers life sciences, l.p. ("life sciences", and together with 667, the "funds") purchased 785,045 and 1,801,161 shares of the common stock, respectively of acadia pharmaceuticals, inc. (the "issuer"), pursuant to an underwritten public offering.
f3 after giving effect to the transactions reported herein and as a result of their ownership interest in baker biotech capital (gp), llc, julian c. baker and felix j. baker each may be deemed to have an indirect pecuniary interest in the issuer's shares of common stock reported in column 5 of table i directly held by 667, a limited partnership of which the sole general partner is baker biotech capital, l.p., a limited partnership of which the sole general partner is baker biotech capital (gp), llc, due to baker biotech capital, l.p.'s right to receive an allocation of a portion of the profits from 667.
f5 baker bros. advisors lp (the "adviser") serves as the investment adviser to the funds. in connection with the services provided by the adviser, the adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the funds. baker bros. advisors (gp) llc (the "adviser gp") is the adviser's sole general partner. julian c. baker and felix j. baker are principals of the adviser gp. the adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the funds. the general partners of the funds have relinquished to the adviser all discretion and authority with respect to the investment and voting power of the securities held by the funds. pursuant to agreements between julian c. baker, dr. biggar and the adviser, the adviser has investment and dispositive power over the stock options and any shares received as a result of the exercise of options. (continued in footnote 6)
f6 julian c. baker, felix j. baker, the adviser gp and the adviser disclaim beneficial ownership of the securities held directly by the funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of julian c. baker, felix j. baker, the adviser gp or the adviser is a beneficial owner of such securities for purposes of section 16 or any other purpose.


Filed on 2016-01-08 by 14159, L.P. SEC CIK 1551138 Form 4

Accession 0001638599-16-000500.txt Sec File: edgar/data/1551138/0001638599-16-000500-index.htm

2016-01-07 14159 Lp (CIK 1551138) through See Footnotes

Invested in Acadia Pharmaceuticals Inc remaining shares owned 452540

Common Stock Acadia Pharmaceuticals Inc Acad

f1 as a result of their ownership interest in 14159 capital (gp), llc, felix j. baker and julian c. baker may be deemed to have an indirect pecuniary interest in 452,540 shares of common stock of the issuer beneficially owned by 14159, l.p. ("14159"), a limited partnership of which the sole general partner is 14159 capital, l.p., a limited partnership of which the sole general partner is 14159 capital (gp), llc, due to 14159 capital, l.p.'s right to receive an allocation of a portion of the profits from 14159.
f5 baker bros. advisors lp (the "adviser") serves as the investment adviser to the funds. in connection with the services provided by the adviser, the adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the funds. baker bros. advisors (gp) llc (the "adviser gp") is the adviser's sole general partner. julian c. baker and felix j. baker are principals of the adviser gp. the adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the funds. the general partners of the funds have relinquished to the adviser all discretion and authority with respect to the investment and voting power of the securities held by the funds. pursuant to agreements between julian c. baker, dr. biggar and the adviser, the adviser has investment and dispositive power over the stock options and any shares received as a result of the exercise of options. (continued in footnote 6)
f6 julian c. baker, felix j. baker, the adviser gp and the adviser disclaim beneficial ownership of the securities held directly by the funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of julian c. baker, felix j. baker, the adviser gp or the adviser is a beneficial owner of such securities for purposes of section 16 or any other purpose.